Comparative Pharmacology
Head-to-head clinical analysis: BETAPEN VK versus DYCILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPEN VK versus DYCILL.
BETAPEN-VK vs DYCILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and disrupting peptidoglycan synthesis, leading to cell lysis.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections; up to 500 mg orally every 4 hours for severe infections.
250 mg orally every 6 hours or 500 mg orally every 12 hours.
None Documented
None Documented
0.5-1 hour in patients with normal renal function; prolonged to 7-10 hours with creatinine clearance <10 mL/min.
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
Renal excretion accounts for 20-40% of the dose as unchanged drug via tubular secretion and glomerular filtration; biliary/fecal excretion is minimal (<10%).
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic